United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - cefdinir 300 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.  caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains) (see cli

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - cefdinir 300 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. adults and adolescents: community-acquired pneumonia: caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhali

United States - English - NLM (National Library of Medicine)

lupin limited - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - cefdinir 300 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.  caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains) (see cli

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - cefdinir 300 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.  caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains) (see cli

United States - English - NLM (National Library of Medicine)

bluepoint laboratories - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - cefdinir 300 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains) (see

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - cefdinir 300 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. community-acquired pneumonia caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains) (see clinical studies ). acute exacerbations of chronic bronchitis caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains). acute maxillary sinusitis caused by haemophilus influenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains). note: for information on use in pediatric patients, see pediatric use and dosage andadministration . pharyngitis/tonsillitis caused by streptococcus pyogenes (see clinical studies ). note: cefdinir is effective in the eradication of s. pyogenes from the oropharynx. cefdinir has not, however, been studied for the prevention of rheumatic fever following s. pyogenes pharyngitis/tonsillitis. only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. uncomplicated skin and skin structure infections caused by staphylococcus aureus (including β-lactamase producing strains) and streptococcus pyogenes . acute bacterial otitis media caused by haemophilus influenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains). pharyngitis/tonsillitis caused by streptococcus pyogenes (see clinical studies ). note: cefdinir is effective in the eradication of s. pyogenes from the oropharynx. cefdinir has not, however, been studied for the prevention of rheumatic fever following s. pyogenes pharyngitis/tonsillitis. only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. uncomplicated skin and skin structure infections caused by staphylococcus aureus (including β-lactamase producing strains) and streptococcus pyogenes . cefdinir capsules are contraindicated in patients with known allergy to the cephalosporin class of antibiotics.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - cefdinir 300 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir capsules, usp are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. community-acquired pneumonia caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains) (see clinical studies ). acute exacerbations of chronic bronchitis caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains). acute maxillary sinusitis caused by haemophilus influenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains). note: for information on use in pediatric patients, see pediatric use   and dosage and administration . pharyngitis/tonsillitis caused by streptococcus pyogenes (see clinical studies ). note: cefdinir is effective in the eradication of s. pyogenes from the oropharynx. cefdinir has not, however, been studied for the prevention of rheumatic fever following s. pyogenes pharyngitis/tonsillitis. only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. uncomplicated skin and skin structure infections caused by staphylococcus aureus (including β-lactamase producing strains) and streptococcus pyogenes . acute bacterial otitis media caused by haemophilus influenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains). pharyngitis/tonsillitis caused by streptococcus pyogenes (see clinical studies ). note: cefdinir is effective in the eradication of s. pyogenes from the oropharynx. cefdinir has not, however, been studied for the prevention of rheumatic fever following s. pyogenes pharyngitis/tonsillitis. only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. uncomplicated skin and skin structure infections caused by staphylococcus aureus (including β-lactamase producing strains) and streptococcus pyogenes . cefdinir capsules are contraindicated in patients with known allergy to the cephalosporin class of antibiotics.

United States - English - NLM (National Library of Medicine)

rebel distributors corp - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - cefdinir 300 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. community-acquired pneumonia caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - cefdinir monohydrate (unii: 6e7sn358se) (cefdinir - unii:ci0fao63wc) - cefdinir 250 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir for oral suspension usp and other antibacterial drugs, cefdinir for oral suspension usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir for oral suspension usp is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptibl

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - cefdinir monohydrate (unii: 6e7sn358se) (cefdinir - unii:ci0fao63wc) - cefdinir 125 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir for oral suspension, usp and other antibacterial drugs, cefdinir for oral suspension, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir for oral suspension, usp is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains) (see clinical studies ). caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains). caused by haemophilus influenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains). note : for information on use in pediatric patients, see pediatric use  and dosage and administration . caused by streptococcus pyogenes (see clinical studies ). note : cefdinir is effective in the eradication of s. pyogenes from the oropharynx. cefdinir has not, however, been studied for the prevention of rheumatic fever following s. pyogenes pharyngitis/tonsillitis. only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. caused by staphylococcus aureus (including β-lactamase producing strains) and streptococcus pyogenes . acute bacterial otitis media caused by haemophilus influenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains). caused by streptococcus pyogenes (see clinical studies ). note : cefdinir is effective in the eradication of s. pyogenes from the oropharynx. cefdinir has not, however, been studied for the prevention of rheumatic fever following s. pyogenes pharyngitis/tonsillitis. only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. caused by staphylococcus aureus (including β-lactamase producing strains) and streptococcus pyogenes . cefdinir for oral suspension is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.